Virtual | October 8-10, 2024
TUESDAY, OCTOBER 8, 2024
8:00 AM – 10:45 AM
SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
10:45 AM – 1:20 PM
SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
1:20 PM – 3:00 PM
LUNCH BREAK
3:00 PM – 5:30 PM
PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
WEDNESDAY, OCTOBER 9, 2024
8:00 AM – 10:30 AM
SESSION II (PART 1): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
10:30 AM – 12:30 PM
SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
12:30 PM – 2:00 PM
LUNCH BREAK
2:00 PM – 6:00 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
THURSDAY, OCTOBER 10, 2024
8:00 AM – 12:00 PM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
12:00 PM – 1:00 PM
LUNCH BREAK
1:00 PM – 2:00 PM
PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
2:00 PM – 2:30 PM
PRESENTATION OF WINNING ABSTRACTS
2:30 PM – 4:00 PM
GENERAL DISCUSSION
4:00 PM
ADJOURN
.8:15 am SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Peter Albers, MD, Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ) Heidelberg, Germany
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
8:30 am Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening
8:30 am Topic 1A: Year in Review: Emerging Data and Advances in Screening
Sigrid Carlsson, MD, PHD, MPH
8:40 am Q & A
8:42 am Topic 1B: Update on the PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)
Peter Albers, MD
8:52 am Q & A
8:54 am Topic 1C: Update on the PROFILE and IMPACT Studies
Jana McHugh, MB, BCh, BAO, Clinical Research Fellow, Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology, Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom
9:04 am Q & A
9:06 am Topic 1D: Multi-Cancer Early Detection (MCED)
9:06 am Overview of MCED – Performance and Impact on Prostate Cancer
Erik A. Klein, MD, Distinguished Scientist, GRAIL; and Emeritus Andrew C. Novick Distinguished Professor and Chair, Glickman Urologic and Kidney Institute and Cleveland Clinic Lerner College of Medicine
9:16 am Q & A
9:18 am MRI-Based Prostate Cancer Screening in an Era of MCEDs
Mark Emberton, MD, Dean, Faculty of Medical Sciences, and Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom
9:28 am Q & A
9:30 am Topic 1E: Update on PRAISE-U Project – European Union Initiative in PC Screening
Monique Roobol, PhD, Professor of Decision Making in Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands
9:40 am Q & A
9:42 am Topic 1F: the BARCODE 1 Study: Enrichment of Prostate Cancer Detection in Those with Higher Polygenic Risk
Ros Eeles, PhD, FRCP, FRCR, Professor of Oncogenetics, The Institute of Cancer Research, Royal Marsden Hospital, University of London; and Honorary Consultant in Cancer Genetics and Clinical Oncology, National Health Service (NHS) Foundation Trust, London, United Kingdom
9:52 am Q & A
9:54 am – 10:15 am Panel Discussion: “Smart” Prostate Cancer Screening
10:15 am – 10:45 am COFFEE BREAK
10:45 am SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
Clare M. C. Tempany, MD, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women’s Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization
10:45 am Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
10:45 am Topic 2A: Current and Emerging Molecular and Genetic Diagnostics
10:45 am Overview of Liquid Biomarkers
E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal
10:55 am Q & A
10:57 am – 11:10 am Panel Discussion: Molecular and Genetic Diagnostics
11:10 am Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies
11:10 am OPTIMUM Trial – A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer
Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation PI-RADS. Sponsored by Exact Imaging.
11:22 am MRI PI-RADS Standardization and Clinical Evaluation
Clare M. C. Tempany, MB BAO BCh
11:32 am Q & A
11:34 am Quality Improvement American College of Radiology Program in Prostate MRI
Andrei Purysko, MD, Associate Professor of Radiology, Cleveland Clinic Lerner College of Medicine; Section Head, Abdominal Imaging; Staff, Nuclear Medicine Department; Staff, Glickman Urological and Kidney Institute
11:44 am Q & A
11:46 am Bi-Parametric Optimized 15 min Protocol with Deep Learning Acceleration for Prostate MRI – Are we there yet?
.Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School. Sponsored by Siemens.
11:56 am Q & A
11:58 am Optimizing MRI Techniques for Prostate Cancer Diagnosis
Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
12:08 pm Q & A
12:10 pm – 12:30 pm Panel Discussion: Imaging Modalities and Targeted Biopsies
12:30 pm Topic 3: NCCN Guidelines for Early Detection of Prostate Cancer 2024
Preston Sprenkle, MD
12:40 pm Q & A
12:42 pm – 1:20 pm General Discussion
Moderators, Speakers and Mark Katz, MD, Clinical Associate Professor of Urology, Boston University School of Medicine
1:20 pm – 3:00 pm LUNCH BREAK
3:00 pm PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
Moderators:
Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
.
Amita Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center
.
Baris Turkbey, MD, Senior Clinician, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health
.
.
3:00 pm Artificial Intelligence and Management of Big Data: Recent Advances, Fundamental Challenges and Future Vision for Standardization, Integration, and Clinical Applications
Paul Boutros, PhD, MBA
3:10 pm Q & A
3:12 pm Leveraging Big Data in Surgery through HL7 Integration and Computer Vision
Archan Khandekar, MD, Instructor, Desai Sethi Urology Institute, Miller School of Medicine, University of Miami
3:22 pm Q & A
3:24 pm Norwegian PSA Registry
Jan Oldenburg, MD, PhD, Department of Oncology, Akershus University Hospital (Ahus) and Professor, University of Oslo, Norway
3:34 pm Q & A
3:36 pm AI and Health Disparities
Rakesh Shiradkar, PhD, Assistant Professor, BioHealth Informatics, Indiana University
3:46 pm Q & A
3:48 pm Connected Care and Latest Developments in Prostate Cancer Management
Ilya Gipp, MD, PhD, Global Clinical Leader – Oncology, GE Healthcare
3:58 pm Q & A
4:00 pm – 5:30 pm Panel Discussion: Moderators, Speakers
8:00 am SESSION II (PART 1): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
.
Mohammed Shahait, MBBS, JBU, Consultant of Urology & Robotic Surgery; and Clinical Instructor of Urology at Sharjah University, Fellow of the Endourology Society, and Fellow of the Society of Urology Robotic Surgeons, Dubai, United Arab Emirates; and Jordan
8:10 am Topic 1: Panel on Multiomics of Prostate Cancer
8:10 am Topic 1A: Genomics and Natural History of MRI Invisible vs Visible Cancers
Laurence Klotz, MD
8:22 am Topic 1B: Emerging Data and Advances in Diagnostics of Prostate Cancer – Year in Review
Paul Boutros, PhD, MBA
8:32 am Q & A
8:34 am Topic 1C: Molecular and Multi-Modality Imaging for Visualization and Staging of the Initial and Recurrent Disease
8:34 am Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance
Adam Kinnaird, MD, PhD, FRCSC, Frank and Carla Sojonky Chair in Prostate Cancer Research; Assistant Professor, Division of Urology, Department of Surgery; and Adjunct Assistant Professor, Department of Oncology, University of Alberta, Canada
8:44 am Q & A
8:46 am MRI
Baris Turkbey, MD
8:56 am Molecular Imaging
Stefano Fanti, MD, Professor, Department of Medical and Surgical Sciences, Head of Nuclear Medicine, University of Bologna, Italy
.
.
9:06 am Q & A
9:08 am Criteria for the Development and Validation of Radiomic Tests in Diagnosis and Treatment of Prostate Cancer
Erich Huang, PhD, Mathematical Statistician, National Cancer Institute
.
.
9:18 am Q & A
9:20 am Topic 1D: Novel and Emerging Pathological Factors in Localized and Recurrent Prostate Cancer
Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago
.
9:30 am Q & A
9:32 am Topic 1E: Integration of MRI with Histology, Genomics, and Proteomics
Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
.
9:42 am Q & A
9:42 am – 9:58 am Panel Discussion: Multiomics – Moderators and Speakers
9:58 am – 10:30 am COFFEE BREAK
10:30 am SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Carlos A. Buchpiguel, MD, PhD, Director of Molecular Imaging and Nuclear Medicine Division; and Full Professor, Department of Radiology and Oncology, São Paulo University School of Medicine, São Paulo -SP, Brazil
Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF
Stefano Fanti, MD, Professor and Director, Specialty School of Nuclear Medicine, and Director, Nuclear Medicine Division and PET Unit, Policlinico S. Orsola, University of Bologna, Italy
Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign
Almudena Zapatero, MD PhD, Senior Consultant, Radiation Oncology, and Head of Laboratory for Genito-Urinary Tumors, Research Investigative Institute IIS-IP HUP, Hospital Universitario de La Princesa, Madrid, Spain
..
10:30 am Topic 2: Year in Review – Emerging Advances in Diagnosis and Treatment
Matthew Cooperberg, MD, MPH
10:40 am Q & A
10:42 am Topic 3: Away from the Gleason Score and Towards Quantification of Pattern 4 for Treatment Decision Making in Localized Prostate Cancer
Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center
10:52 am Q & A
10:54 am Topic 4: Artificial Intelligence for Improving Prostate Cancer Management
Wayne Brisbane, MD, Assistant Professor of Urology, UCLA
11:04 am Q & A
11:06 am Topic 5: Current Status of External Validation of Inter-Reader Reproducibility for the Prostate Imaging Quality (PI-QUAL)
Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China
11:16 am Q & A
11:18 am Topic 6: Integration of Precision Diagnosis and Precision Treatment
11:18 am Topic 6A: Integrated Diagnostics (Radiogenomics) for Active Surveillance, Surgical and Radiation Treatment
Sanoj Punnen, MD, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Vice Chair of Research, Department of Urology Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine
11:28 am Q & A
11:30 am Topic 6B: Image-Guided, Minimally -Invasive Treatment
11:30 am Emerging Role of Focal Treatment in Patient Management
Bruno Nahar, MD, Associate Professor of Urologic Oncology, Eric and Elizabeth Feder Endowed Chair in Urologic Oncology Research, Desai Sethi Urology Institute, University of Miami Miller School of Medicine
11:40 am Q & A
11:42 am Topic 6C: Radiation Treatment
Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University
11:52 am Q & A
11:54 pm – 12:30 pm Panel Discussion: Integration of Precision Diagnosis and Treatment
12:30 pm – 2:00 pm LUNCH BREAK
2:00 pm SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Moderators:..
Steven Eric Finkelstein, MD, DABR, FACRO, Director of the Center of Advanced Radiation Excellence (CARE); and Director, Radiation Oncology Research, Associated Medical Professionals, Syracuse, NY
Raluca Mititelu, MD, PhD, Lecturer, University of Medicine and Pharmacy Carol Davila Central University Emergency Military Hospital Bucharest, Romania
David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program
.
2:10 pm Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
2:10 pm Topic 1A: Review of the New Standard in Treatment: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors
Marc Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, and Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; and Special Advisor, Oncologic Drugs Advisory Committee of the FDA
2:20 pm Q & A
2:22 pm Topic 1B: NCCN Guidelines for Management of Advanced PC
Kelvin A. Moses, MD, PhD, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel
2:32 pm Q & A
2:34 pm Topic 1C: Sequencing of Treatment
Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors.
2:44 pm Q & A
2:46 pm Topic 1D: Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls:
Sean P. Collins MD, PhD, Professor of Radiation Medicine and Director, CyberKnife Prostate Program, Department of Radiation Medicine, Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center. Sponsored by Blue Earth Diagnostics.
Patrick Soon-Shiong, MD, Executive Chairman, Global Chief Scientific and Medical Officer, ImmunityBio
3:06 pm Q & A
3:10 pm – 3:30 pm COFFEE BREAK
3:30 pm Topic 1F: Novel Targeted Treatment
Recent Advances and Future Directions in Medical Oncology; Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University
3:40 pm Q & A
3:42 pm Transforming Prostate Cancer Care – The Emerging Role of Radio-Ligand Therapies:
Ilya Gipp, MD, PhD, Global Clinical Leader – Oncology, GE Healthcare. Sponsored by GE Healthcare.
4:02 pm Topic 1G: Immunotherapy
Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment
4:12 pm Q & A
4:14 pm – 4:30 pm Panel Discussion: Standard and Emerging Treatment
4:30 pm Topic 2: Molecular Imaging and Theranostics
4:30 pm Molecular Imaging for Staging and Treatment Planning, including Patient Eligibility and Selection for LuPSMA Therapy
Hong Song, MD, PhD, Assistant Professor, Nuclear Medicine/Radiology, Stanford University
4:40 pm – 4:50 pm Panel Discussion: Molecular Imaging and Theranostics
4:50 pm Topic 3: Precision Diagnostics and Emerging Treatment Strategies – Case Studies:
David Nanus, MD
5:00 pm – 5:15 pm Panel: Case Studies
5:15 pm – 5:30 pm General Discussion: Speakers, Moderators, and Brandon Mancini
Brandon Mancini, MD, MBA, Medical Director, BAMF Health
8:00 am SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
Moderators:
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
Derek Lomas, MD, Assistant Professor of Urology, Mayo Clinic
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
8:10 am Topic 1: Overview
Mark Emberton, MD
8:20 am Q & A
8:22 am Topic 2: Focal Therapy for Prostate Cancer – How to Choose an Optimal Weapon?
David Margel, MD, PhD, Founder, Rabin Medical Center and BRCA clinic, Member, Early Detection Committee at the Cancer War Society
8:32 am Q & A
8:34 am Topic 3: Patient Selection for Focal Therapy – Radiologic Perspective
8:34 am Imaging and Patient Selection
Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, RadboudUMC Nijmegen, The Netherlands; and Professor, Robotics and Mechanics Group, University of Twente, the Netherlands
8:44 am Q & A
8:46 am Multiomics and Patient Selection
John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
8:56 am Topic 4: Patient Selection for Prostate Cancer Focal Therapy – Urologic Perspective
Geoffrey Sonn, MD, Assistant Professor of Urology and Radiology, Stanford University School of Medicine
9:06 am Q & A
9:08 am Topic 5: Focal Therapy Recurrences and Management
Abhinav Sidana, MD, MPH, Associate Professor of Surgery, Director of Focal Therapy, University of Chicago
9:18 am Q & A
9:20 am Topic 6: Prostate Cancer Ablation using MRI-Guided Transurethral Ultrasound (TULSA-PRO)
Ram A. Pathak, MD, Associate Professor, Vice-Chair of Research, Department of Urology, P.E.D. Mayo Clinic Comprehensive Cancer Center, R.A.D. Mayo Clinic Alix School of Medicine, Mayo Clinic Florida, Sponsored by Profound Medical
9:30 am – 9:50 am COFFEE BREAK
9:50 am Topic 6: Panel on Addressing Fundamental Challenges in Clinical Acceptance and Adoption of Image-Guided Treatment – Perspective from the AdMeTech Foundation’s International Working Group
9:50 am Introduction – Post Treatment Assessment and Creating Imaging-Based Short- and Intermediate- Term Patient Outcomes
Faina Shtern, MD
10:00 am Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up
Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
10:10 am Q & A
10:12 am PI-FAB Standardization of MRI Reporting
Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, Honorary Consultant Radiologist, University College London Hospitals
10:22 am Q & A
10:24 am TARGET Consensus on Post-Treatment MRI Reporting
Taimur T. Shah, MBBS, BSc (Hons), FRCS (Urol), PhD, Clinical Senior Lecturer & Consultant Urologist, Prostate Cancer MDT Lead, Prostate Cancer UK (PCUK) Clinical Champion Imperial College London & Imperial College Healthcare NHS Trust
10:34 am Q & A
10:36 am University of Toronto Experience – MRI After Focal Treatment
Sangeet Ghai, MD, FRCR, Deputy Chief of Research and Associate Professor, Joint Department of Medical Imaging at the University of Toronto, Canada
10:46 am Q & A
10:48 am – 11:30 am Panel on MRI Reporting – Recommendations and Discussion
Francesco Giganti, MD;
Daniel Margolis, MD;
Sandeep Arora, MBBS, FSAR, Associate Professor of Radiology and Biomedical Imaging, Yale School of Medicine; Giovanni Lughezzani, MD, Staff Physician, Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (MI), and Associate Professor, Humanitas University, Milan, Italy;
Giancarlo Marra, MD, Consultant Urologist and Assistant Professor, Division of Urology, AOU Citta Della Salute e della Scienza, University of Turin, Italy (TBC);
11:30 am – 12:00 pm Panel on Molecular Imaging Post Focal Treatment – Emerging Data and Next Steps
Stefano Fanti, MD;
Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland
11:30 am Emerging Data and Current Plans
Heying Duan, MD, Medical Director, RayzeBio;
Stefano Fanti, MD;
Irene Burger, MD
11:45 am – 12:00 pm Panel on Molecular Imaging – Recommendations and Discussion
Stefano Fanti, MD;
Irene Burger, MD
12:00 pm – 1:00 pm LUNCH BREAK
1:00 pm PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
Moderators:
Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine – Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health
Faina Shtern, MD
1:00 pm Risk Assessment in Black Men
Adam B Murphy, MD, MBA, MSCI
1:10 pm Q & A
1:12 pm Utilization and Disparity Patterns Related to PC Markers
Michael Leapman, MD, MHS, Associate Professor of Urology, Clinical Program Leader, Prostate and Urologic Cancers Program, Yale Cancer Center
1:22 pm Q & A
1:24 pm PROWESS – A Culturally Adapted and Tailored Behavioral Intervention for Black and Latino Men with Metastatic Prostate Cancer
Jamie Jacobs, PhD, Program Director, Center for Psychiatric Oncology & Behavioral Sciences, Director of Caregiving Research, Cancer Outcomes Research Program, Massachusetts General Hospital, and Assistant Professor, Harvard Medical School
1:34 pm Q & A
1:36 pm Outreach Program to Address Racial Disparities in Prostate Cancer Care
Quoc-Dien Trinh, MD, MBA, Chief of Urology, Brigham and Women’s Faulkner Hospital, Co-Director, DanaFarber/Brigham and Women’s Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School
1:46 pm – 2:00 pm Panel Discussion: Health Disparities
2:00 pm – 2:30 pm Presentation of Winning Abstracts
First Place: Extracapsular Extension Risk Assessment and Localization Using an Artificial Intelligence Prostate, Sakina Mohammed Mota, PhD, Data Scientist, Avenda Health
Second Place (Tied):
Performance of an AI-assisted Whole Prostate Gland Segmentation Module for MRI-Guided Transurethral Ultrasound (TULSA) Treatment Planning – Multi-Reader Multi-Case Study: Steven Raman, MD, UCLA, and
Clinical, Pathological and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and mpMRI: Ida Sonni, MD, Project Scientist, UCLA
Third Place (Tied):
Artificial Intelligence Prostate Segmentation Integrated into Treatment Planning Software for MRI-Guided Transurethral Ultrasound Ablation – Initial Real-World Experience: Steven Raman, MD, UCLA; and
Diagnostic Performance of a Locally Developed Multiparametric MRI Scoring System for the Detection of Prostate Cancer After Focal Ablative Therapies in Prostate Cancer – Toronto Score: Sangeet Ghai, MD (Presented in Session IV)
2:30 pm – 4:00 pm General Discussion
4:00 pm ADJOURN